Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Conbercept Intravitreal Injection Safety Study in Wet Age-related Macular Degeneration
CTR20170018Phase 4Completed
- Sponsor
- Chengdu Kanghong Biotechnology Co., Ltd.
- Start
- Feb 2017
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of conbercept in exudative macular degeneration, sponsored by Chengdu Kanghong Biotechnology Co., Ltd.. Started Feb 2017; status: completed.
02
Drugs
conbercept
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on CTR20170018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20170018.